Martin Gouldstone is Chief Business Officer at Sensyne Health Lifesciences, helping to drive organic and inorganic growth for this ethically inspired clinical stage AI business, turning access to proprietary patient data into actionable insights for both caregivers and the Pharmaceutical Industry.
Particular focus on expanding our reach and access in the US market and global Pharmaceutical sector. His 30-year Industry career has spanned research into genetic fingerprinting, clinical research across Pharmaceuticals, Devices and CROs, and lead commercial roles across several platform drug discovery businesses. During this period he focused mainly in oncology and inflammation, signing early-stage licensing and partnership deals with Genentech, Biovitrum and Novo Nordisk, among others.
As well as his scientific and licensing career Martin has spent 7 years in Corporate Finance specialising in M&A, fundraising, disposals and spin outs. He brings all of this experience to his role at Sensyne Health, where he is working across the commercialisation of a unique access model to proprietary patient data and looking for inorganic growth opportunities to further scale the business.